Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SARS
MCID: SVR001
MIFTS: 62

Severe Acute Respiratory Syndrome (SARS)

Categories: Blood diseases, Infectious diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Severe Acute Respiratory Syndrome

About this section

MalaCards integrated aliases for Severe Acute Respiratory Syndrome:

Name: Severe Acute Respiratory Syndrome 12 74 52 58 3 43 15 17 71
Sars 12 52 58 3
Sars-Cov Infection 12
Sars-1 58

Characteristics:

Orphanet epidemiological data:

58
severe acute respiratory syndrome
Prevalence: <1/1000000 (Europe); Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Respiratory diseases Neuronal diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare respiratory diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:2945
ICD9CM 34 079.82
MeSH 43 D045169
NCIt 49 C85064
SNOMED-CT 67 398447004
ICD10 32 J12.81 U04 U04.9
MESH via Orphanet 44 D045169
ICD10 via Orphanet 33 U04.9
UMLS via Orphanet 72 C1175175
Orphanet 58 ORPHA140896
UMLS 71 C1175175
Sources

Summaries for Severe Acute Respiratory Syndrome

About this section
CDC : 3 Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus called SARS-associated coronavirus (SARS-CoV). SARS was first reported in Asia in February 2003. The illness spread to more than two dozen countries in North America, South America, Europe, and Asia before the SARS global outbreak of 2003 was contained. Since 2004, there have not been any known cases of SARS reported anywhere in the world. The content in this website was developed for the 2003 SARS epidemic. But some guidelines are still being used. Any new SARS updates will be posted on this website.

MalaCards based summary : Severe Acute Respiratory Syndrome, also known as sars, is related to sarcoidosis 1 and covid-19, and has symptoms including fever, headache and dry cough. An important gene associated with Severe Acute Respiratory Syndrome is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ziprasidone and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include respiratory tract, testes and lung, and related phenotypes are fever and abnormality of the cardiovascular system

Disease Ontology : 12 A Coronavirus infection that results in infection located in respiratory tract, has material basis in SARS coronavirus (SARS-CoV), which is transmitted by droplet spread of respiratory secretions, transmitted by ingestion of contaminated food, or transmitted by fomites. The infection has symptom fever, has symptom headache, has symptom body aches, has symptom dry cough, and has symptom hypoxia.

Wikipedia : 74 Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by... more...

Sources

Related Diseases for Severe Acute Respiratory Syndrome

About this section

Diseases in the Respiratory Failure family:

Severe Acute Respiratory Syndrome

Diseases related to Severe Acute Respiratory Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 889)
# Related Disease Score Top Affiliating Genes
1 sarcoidosis 1 32.4 TNF HLA-A CXCL10 CCL5 CCL2
2 covid-19 31.6 TMPRSS2 IL6 CTSL ACE2
3 respiratory failure 31.1 TNF IL6 IL10 CXCL8 CXCL10 CCL5
4 middle east respiratory syndrome 31.0 TMPRSS2 SH2D3A IRF3 IFNB1 CXCL10 CTSL
5 neutropenia 30.8 TNF IL6 IL10 IFNA1 CXCL8
6 bronchopneumonia 30.7 TNF IL6 IL10 CXCL8
7 adult respiratory distress syndrome 30.7 TNF IL6 IL10 CXCL8
8 avian influenza 30.7 TNF IL6 IFNA1 DDX58 CXCL8 CXCL10
9 gastroenteritis 30.7 TNF IL6 IL10 IFNA1 CXCL8
10 pulmonary edema 30.7 TNF IL10 CXCL8
11 west nile virus 30.7 IRF3 IFNA1 DDX58 CLEC4M CD209
12 myocarditis 30.7 TNF IL6 IL10 IFNA1 CCL2
13 venezuelan equine encephalitis 30.6 IFNB1 IFNA1 CXCL10 CCL2
14 vaccinia 30.6 TNF IRF3 IL6 IFNB1 IFNA1
15 allergic encephalomyelitis 30.6 CCL5 CCL2
16 kawasaki disease 30.6 TNF IL6 IL10 CCL2
17 common cold 30.6 TNF IL6 IL10 CXCL8 CCL5
18 dengue disease 30.5 TNF IFNB1 IFNA1 CD209 CCL5
19 bacterial pneumonia 30.5 TNF IL6 IL10 CXCL8
20 hepatitis a 30.5 TNF IL10 IFNA1 CXCL8 CXCL10
21 bronchitis 30.5 TNF IL6 IL10 CXCL8 CXCL10 CCL5
22 orchitis 30.5 TNF IL6 IL10
23 diarrhea 30.5 TNF IRF3 IL6 IL10 IFNB1 IFNA1
24 vasculitis 30.5 TNF IL6 IL10 CCL2
25 hypereosinophilic syndrome 30.5 IL10 IFNA1 CXCL8 CCL5
26 lung disease 30.4 TNF IL6 IL10 CXCL8 CXCL10 CCL5
27 bronchiolitis obliterans 30.4 TNF IL6 IL10 CXCL8
28 sleeping sickness 30.4 IL6 IL10 CTSL
29 acquired immunodeficiency syndrome 30.4 TNF IL6 IL10 IFNA1
30 allergic contact dermatitis 30.4 TNF IL6 IL10 CXCL8 CCL2
31 rhinitis 30.4 TNF IL6 IL10 CXCL8 CCL5
32 mycobacterium tuberculosis 1 30.4 TNF IL10 IFNB1 CXCL10 CD209
33 pulmonary tuberculosis 30.4 TNF IL6 IL10 CCL2
34 syphilis 30.4 TNF IL6 CD209
35 chlamydia pneumonia 30.4 TNF IL6 IL10 CXCL8 CCL2
36 chlamydia 30.4 TNF IL6 IL10 CXCL8 CCL2
37 pericarditis 30.4 TNF IL6 CXCL8
38 disseminated intravascular coagulation 30.3 TNF IL6 IL10
39 haemophilus influenzae 30.3 TNF CXCL8
40 lymphocytic choriomeningitis 30.3 IRF3 IL6 DDX58 CXCL8
41 schistosomiasis 30.3 TNF IL10 CCL5 CCL2
42 leukostasis 30.3 TNF IL6 CCL2
43 contact dermatitis 30.3 TNF IL6 IL10 CXCL8 CXCL10 CCL2
44 toxic shock syndrome 30.3 TNF IL6 IL10 CXCL8
45 streptococcal toxic-shock syndrome 30.3 TNF IL6 CXCL8
46 colitis 30.2 TNF IL6 IL10 CXCL8
47 chagas disease 30.2 TNF IL6 IL10 CXCL8 CCL5 CCL2
48 mycoplasma pneumoniae pneumonia 30.2 TNF IL6 IL10
49 endophthalmitis 30.2 TNF IL6 CXCL8
50 endocarditis 30.2 TNF IL6 IL10 CXCL8

Graphical network of the top 20 diseases related to Severe Acute Respiratory Syndrome:



Diseases related to Severe Acute Respiratory Syndrome
Sources

Symptoms & Phenotypes for Severe Acute Respiratory Syndrome

About this section

Human phenotypes related to Severe Acute Respiratory Syndrome:

58 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 Frequent (79-30%)
2 abnormality of the cardiovascular system 58 Occasional (29-5%)
3 dyspnea 58 Frequent (79-30%)
4 immunodeficiency 58 Frequent (79-30%)
5 myalgia 58 Frequent (79-30%)
6 cough 58 Very frequent (99-80%)
7 neoplasm 58 Occasional (29-5%)
8 diabetes mellitus 58 Occasional (29-5%)
9 headache 58 Frequent (79-30%)
10 respiratory failure requiring assisted ventilation 58 Occasional (29-5%)
11 respiratory distress 58 Frequent (79-30%)
12 hypoxemia 58 Occasional (29-5%)
13 acute kidney injury 58 Very rare (<4-1%)
14 acute infectious pneumonia 58 Occasional (29-5%)
15 chronic lung disease 58 Occasional (29-5%)
16 pharyngitis 58 Occasional (29-5%)

Symptoms:

12
  • • fever
  • • headache
  • • dry cough
  • • body aches
  • • hypoxia

UMLS symptoms related to Severe Acute Respiratory Syndrome:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Severe Acute Respiratory Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.44 ACE2 CCL2 CCL5 CLEC4M CXCL10 DDX58
Sources

Drugs & Therapeutics for Severe Acute Respiratory Syndrome

About this section

Drugs for Severe Acute Respiratory Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 579)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ziprasidone Approved Phase 4 146939-27-7 60854
2
Liraglutide Approved Phase 4 204656-20-2 44147092
3
Glucagon Approved Phase 4 16941-32-5
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Azithromycin Approved Phase 4 83905-01-5 447043 55185
10
Losartan Approved Phase 4 114798-26-4 3961
11
Ibuprofen Approved Phase 4 15687-27-1 3672
12
Protein C Approved Phase 4
13
Captopril Approved Phase 4 62571-86-2 44093
14
Clarithromycin Approved Phase 4 81103-11-9 84029
15
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
16
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
17
Budesonide Approved Phase 4 51333-22-3 63006 5281004
18
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
19
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
20
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
21
Dalteparin Approved Phase 4 9005-49-6
22
Eprosartan Approved Phase 4 133040-01-4 5281037
23
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
24
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
25
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
26
Trandolapril Approved Phase 4 87679-37-6 5484727
27
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
28
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
29
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
30
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
31
Felodipine Approved, Investigational Phase 4 72509-76-3 3333
32
Fosinopril Approved Phase 4 98048-97-6 55891
33
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
34
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
35
Nifedipine Approved Phase 4 21829-25-4 4485
36
Metolazone Approved Phase 4 17560-51-9 4170
37
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
38
Amlodipine Approved Phase 4 88150-42-9 2162
39
Verapamil Approved Phase 4 52-53-9 2520
40
Enalaprilat Approved Phase 4 76420-72-9 6917719
41
Chlorthalidone Approved Phase 4 77-36-1 2732
42
Ramipril Approved Phase 4 87333-19-5 5362129
43
Indapamide Approved Phase 4 26807-65-8 3702
44
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
45
Bendroflumethiazide Approved Phase 4 73-48-3 2315
46
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
47
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
48
Nitrendipine Approved, Investigational Phase 4 39562-70-4 4507
49
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
50
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3

Interventional clinical trials:

(show top 50) (show all 1464)
# Name Status NCT ID Phase Drugs
1 An Open Clinical Trial to Evaluate Ganovo（Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04291729 Phase 4 Ganovo+ritonavir+/-Interferon nebulization
2 An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04345276 Phase 4 Danoprevir+Ritonavir
3 Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms Completed NCT00460538 Phase 4
4 Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up Completed NCT02526030 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
5 Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II) Completed NCT02305823 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
6 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year Completed NCT02534363 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
7 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
8 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
9 Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection Recruiting NCT04340557 Phase 4 Losartan
10 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate Recruiting NCT04346667 Phase 4 Hydroxychloroquine Sulfate Regular dose;Hydroxychloroquine Sulfate Loading Dose;Chloroquine;Placebo
11 Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial Recruiting NCT04334629 Phase 4 Ibuprofen
12 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate Recruiting NCT04351191 Phase 4 Hydroxychloroquine Sulfate Regular dose;Hydroxychloroquine Sulfate Loading Dose;Chloroquine;Placebo
13 Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome Recruiting NCT04341493 Phase 4 Nitazoxanide 500 MG;Hydroxychloroquine
14 Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide Recruiting NCT04406246 Phase 4 Nitazoxanide 500Mg Oral Tablet
15 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Recruiting NCT04390464 Phase 4 Ravulizumab;Baricitinib
16 The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial Recruiting NCT04330300 Phase 4 Thiazide or Thiazide-like diuretics;Calcium Channel Blockers;ACE inhibitor;Angiotensin receptor blocker
17 PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease Recruiting NCT04335786 Phase 4 Valsartan (Diovan);Placebo oral tablet
18 A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure. Recruiting NCT04326920 Phase 4 Sargramostim
19 Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia Recruiting NCT04355637 Phase 4 Inhaled budesonide
20 A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial Recruiting NCT04414267 Phase 4
21 Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses Recruiting NCT04348370 Phase 4
22 A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection Recruiting NCT04252885 Phase 4 Lopinavir and Ritonavir Tablets;Arbidol
23 A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment Recruiting NCT04384380 Phase 4 Hydroxychloroquine Sulfate 200 MG [Plaquenil]
24 Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial Recruiting NCT04353596 Phase 4 ACE inhibitor, angiotensin receptor blocker
25 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial Recruiting NCT04405999 Phase 4 Bromhexine Hydrochloride
26 Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Recruiting NCT04394117 Phase 4 Angiotensin Receptor Blockers
27 The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation Recruiting NCT04377750 Phase 4 Tocilizumab
28 Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia Recruiting NCT04355026 Phase 4 Bromhexine Oral Tablet and/or hydroxychloroquine tablet
29 Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection Recruiting NCT04411667 Phase 4 Octagam
30 Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications Recruiting NCT04331600 Phase 4 Chloroquine phosphate
31 Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE Recruiting NCT04373707 Phase 4 Enoxaparin;Enoxaparin
32 COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19 Recruiting NCT04360824 Phase 4 Intermediate dose thromboprophylaxis;Standard of Care thromboprophylaxis
33 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Recruiting NCT02735707 Phase 4 Fixed-duration Hydrocortisone;Shock-dependent hydrocortisone;Ceftriaxone;Moxifloxacin or Levofloxacin;Piperacillin-tazobactam;Ceftaroline;Amoxicillin-clavulanate;Macrolide administered for 3-5 days;Macrolide administered for up to 14 days;Five-days oseltamivir;Ten-days oseltamivir;Lopinavir/ritonavir;Hydroxychloroquine;Hydroxychloroquine + lopinavir/ritonavir;Interferon-β1a;Anakinra;Fixed-duration higher dose Hydrocortisone;Tocilizumab;Sarilumab
34 Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection Active, not recruiting NCT04316377 Phase 4 Hydroxychloroquine Sulfate
35 Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial Active, not recruiting NCT04417335 Phase 4
36 Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury Enrolling by invitation NCT04397510 Phase 4 Heparin;0.9% Sodium-chloride
37 An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Enrolling by invitation NCT04350671 Phase 4 Interferon Beta-1A;Lopinavir / Ritonavir;Single Dose of Hydroxychloroquine
38 Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Enrolling by invitation NCT04350684 Phase 4 Umifenovir;Interferon-β 1a;Lopinavir / Ritonavir;Single Dose of Hydroxychloroquine;Standards of Care
39 Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up Enrolling by invitation NCT02532491 Phase 4 Aripiprazole;Risperidone
40 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole and Risperidone Over 3 Years Enrolling by invitation NCT03883204 Phase 4 Aripiprazole;Risperidone
41 Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 3-year Follow-up Enrolling by invitation NCT03090503 Phase 4 Aripiprazole;Risperidone
42 Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes Not yet recruiting NCT04341935 Phase 4 Linagliptin;Insulin regimen
43 Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial Not yet recruiting NCT04394377 Phase 4 Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed;Group 2: control group with enoxaparin 40mg/d
44 Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial Not yet recruiting NCT04382625 Phase 4 Hydroxychloroquine
45 Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial Not yet recruiting NCT04359615 Phase 4 Favipiravir;Hydroxychloroquine
46 Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease Not yet recruiting NCT04419025 Phase 4 N-acetylcysteine
47 Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection Not yet recruiting NCT04350086 Phase 4 Treatment with Dexmedetomidine
48 A Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19) Not yet recruiting NCT04363866 Phase 4 Hydroxychloroquine;Placebo
49 COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement Not yet recruiting NCT04369794 Phase 4
50 Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection Not yet recruiting NCT04330495 Phase 4 Hidroxicloroquina;Control group

Search NIH Clinical Center for Severe Acute Respiratory Syndrome

Cochrane evidence based reviews: severe acute respiratory syndrome

Sources

Genetic Tests for Severe Acute Respiratory Syndrome

About this section
Sources

Anatomical Context for Severe Acute Respiratory Syndrome

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Severe Acute Respiratory Syndrome:

19
Respiratory Tract

MalaCards organs/tissues related to Severe Acute Respiratory Syndrome:

40
Testes, Lung, Liver, Kidney, T Cells, Brain, Heart
Sources

Publications for Severe Acute Respiratory Syndrome

About this section

Articles related to Severe Acute Respiratory Syndrome:

(show top 50) (show all 16546)
# Title Authors PMID Year
1
ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens. 61
32438868 2020
2
Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. 61
32306853 2020
3
Inhibition of SARS-CoV 3CL protease by flavonoids. 61
31724441 2020
4
Emergency nurses' perceptions regarding the risks appraisal of the threat of the emerging infectious disease situation in emergency departments. 61
31975652 2020
5
Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. 61
32036774 2020
6
Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV. 61
32471334 2020
7
Animal models for emerging coronavirus: progress and new insights. 61
32378471 2020
8
Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture. 61
32432977 2020
9
Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19. 61
32515685 2020
10
Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. 61
32342724 2020
11
Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. 61
32228226 2020
12
Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. 61
32476607 2020
13
Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19. 61
32338155 2020
14
Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. 61
32562480 2020
15
Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. 61
32475230 2020
16
Mice with humanized-lungs and immune system - an idealized model for COVID-19 and other respiratory illness. 61
32434416 2020
17
Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. 61
32306864 2020
18
The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. 61
32208917 2020
19
Diagnostic value and key features of computed tomography in Coronavirus Disease 2019. 61
32241244 2020
20
Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster. 61
32286155 2020
21
Genetic cluster analysis of SARS-CoV-2 and the identification of those responsible for the major outbreaks in various countries. 61
32525765 2020
22
Analytical comparisons of SARS-COV-2 detection by qRT-PCR and ddPCR with multiple primer/probe sets. 61
32448084 2020
23
Laboratory management for SARS-CoV-2 detection: a user-friendly combination of the heat treatment approach and rt-Real-time PCR testing. 61
32552549 2020
24
Nurse infected with Covid-19 from a provisional dengue patient. 61
32458742 2020
25
Clinical observation and management of COVID-19 patients. 61
32208840 2020
26
Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. 61
32357808 2020
27
Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. 61
32380903 2020
28
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. 61
32207377 2020
29
Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. 61
32301390 2020
30
COVID-19 pandemic - an African perspective. 61
32458760 2020
31
COVID-19: animals, veterinary and zoonotic links. 61
32393111 2020
32
Viral loads in throat and anal swabs in children infected with SARS-CoV-2. 61
32419639 2020
33
Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway. 61
32567972 2020
34
Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. 61
32403995 2020
35
SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. 61
32529952 2020
36
Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. 61
32196410 2020
37
Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. 61
32490731 2020
38
Experimental aerosol survival of SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity. 61
32496967 2020
39
Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. 61
32459137 2020
40
Laboratory diagnosis of emerging human coronavirus infections - the state of the art. 61
32196430 2020
41
COVID-19 Molecular Testing in Korea: Practical Essentials and Answers From Experts Based on Experiences of Emergency Use Authorization Assays. 61
32539299 2020
42
Quality of Ribonucleic Acid Extraction for Real-Time Reverse Transcription-PCR (rRT-PCR) of SARS-CoV-2: Importance of Internal Control Monitoring. 61
32539306 2020
43
A multicriteria approach for risk assessment of Covid-19 in urban district lockdown. 61
32536749 2020
44
COVID-19: Development of a robust mathematical model and simulation package with consideration for ageing population and time delay for control action and resusceptibility. 61
32536738 2020
45
Novel wastewater surveillance strategy for early detection of coronavirus disease 2019 hotspots. 61
32501429 2020
46
Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. 61
32387564 2020
47
Forecasting the timeframe of 2019-nCoV and human cells interaction with reverse engineering. 61
32360608 2020
48
COVID-19 lockdown measures reveal human impact on water transparency in the Venice Lagoon. 61
32470688 2020
49
Wastewater surveillance for population-wide Covid-19: The present and future. 61
32474280 2020
50
Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. 61
32503092 2020
Sources

Variations for Severe Acute Respiratory Syndrome

About this section
Sources

Expression for Severe Acute Respiratory Syndrome

About this section
Search GEO for disease gene expression data for Severe Acute Respiratory Syndrome.
Sources

Pathways for Severe Acute Respiratory Syndrome

About this section

Pathways related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.07 TNF MX1 IRF3 IL6 IL10 IFNB1
2
PEDF Induced Signaling 63
Show member pathways
 13.7 TNF IL6 IL10 IFNB1 IFNA1 CXCL8
3
TGF-Beta Pathway 63
Show member pathways
 13.55 TNF IL6 IL10 IFNB1 IFNA1 CXCL8
4
PAK Pathway 63
Show member pathways
 13.32 TNF IL6 IL10 CXCL8 CXCL10 CCL5
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.18 TNF MX1 IRF3 IL6 IL10 IFNB1
6
PI3K-Akt signaling pathway 36
Show member pathways
 13.04 TNF MX1 IRF3 IL6 IFNB1 IFNA1
7
Human cytomegalovirus infection 36
Show member pathways
 12.99 TNF IRF3 IL6 IFNB1 IFNA1 HLA-A
8
Allograft rejection 1 36
Show member pathways
 12.92 TNF IL6 IL10 IFNA1 HLA-A CXCL8
9
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 12.82 TNF MX1 IRF3 IL6 IL10 IFNB1
10
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.78 TNF IRF3 IL6 IFNB1 IFNA1 CXCL8
11
Herpes simplex virus 1 infection 36
12.78 TNF IRF3 IL6 IFNB1 IFNA1 HLA-A
12
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways
 12.64 IRF3 IL6 IFNB1 IFNA1 DDX58 CXCL10
13
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 65
Show member pathways
 12.62 TNF IRF3 IFNB1 IFNA1 DDX58 CXCL8
14
Interferon gamma signaling 65
Show member pathways
 12.61 MX1 IRF3 IFNB1 IFNA1 HLA-A DDX58
15
NF-kappaB Signaling 4
12.59 TNF IRF3 IL10 IFNA1 DDX58 CXCL10
16
Shigellosis 36
12.45 TNF IRF3 IFNB1 CXCL8 CCL5
17
IL-17 Family Signaling Pathways 64
Show member pathways
 12.39 TNF IL6 CXCL8 CXCL10 CCL2
18
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.39 TNF IL6 IL10 CXCL8 CXCL10 CCL5
19
Folate Metabolism 1
Show member pathways
 12.34 TNF IL6 CCL5 CCL2
20
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.33 TNF IRF3 IL6 IFNB1 CXCL8
21
Toll Comparative Pathway 63
Show member pathways
 12.31 TNF IRF3 IL6 CXCL8
22
C-type lectin receptor signaling pathway 36
Show member pathways
 12.28 TNF IL6 IL10 CLEC4M CD209
23
Bacterial infections in CF airways 22
Show member pathways
 12.26 TNF IL6 IFNB1 CXCL8 CXCL10 CTSL
24
Tuberculosis 36
12.26 TNF IL6 IL10 IFNB1 IFNA1 CLEC4M